Jeffrey A. Barnes, Ph.D.
Affiliations: | 2004 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Jeffrey Barnes"Mean distance: 17.58 (cluster 32)
Parents
Sign in to add mentorMartha Ulbrick Gillette | grad student | 2004 | UIUC | |
(Conservation of Timeless in the mammalian circadian clock.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Mehta-Shah N, Horwitz SM, Ansell S, et al. (2020) NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 522-536 |
Abramson JS, Irwin KE, Frigault MJ, et al. (2019) Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer |
Abramson JS, Arnason JE, LaCasce AS, et al. (2019) Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. Blood |
Karschnia P, Jordan JT, Forst DA, et al. (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood |
Barnes JA, Redd R, Fisher DC, et al. (2018) Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. Hematological Oncology |
Chen ST, Barnes J, Duncan L. (2018) Primary cutaneous B-cell lymphomas- clinical and histopathologic features, differential diagnosis, and treatment. Seminars in Cutaneous Medicine and Surgery. 37: 49-55 |
Horwitz SM, Ansell SM, Ai WZ, et al. (2018) NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 123-135 |
Abramson JS, Redd RA, Barnes JA, et al. (2018) A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma Blood. 132: 1654-1654 |
Bannerji R, Arnason JE, Advani R, et al. (2018) Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes Blood. 132: 1690-1690 |
Bannerji R, Advani RH, Brown JR, et al. (2017) Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy Blood. 130: 1550-1550 |